Literature DB >> 26558534

Retracted: Ebola virus: an introduction and its pathology.

Gurpreet Singh1, Arbind Kumar1, Kashmir Singh1, Jagdeep Kaur1.   

Abstract

The Ebola viruses are causative agent of a severe Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF) in human and other primates. Transmission of EVD occurs through the contact of body fluids from infected persons or animals, making it one of the most epidemic diseases worldwide. Underestimating the Ebola virus has cost loss of precious human lives in recent years. Ebola virus outbreak in year 2014 created a history, affecting a larger population in a wide geographical region of African sub-continent. EVD outbreaks have a case fatality rate of up to 70%. Ebola viruses are endemic in regions of Africa. Ebola viruses mainly target the hepatocytes, endothelial, and macrophage-rich lymphoid tissues and are characterized by immune suppression and a systemic inflammatory response that causes impairment of the vascular, coagulation, and immune systems. This impairment leads to multifocal necrosis and multi organ failure, and thus, in some ways, resembling septic shock. Currently, neither a specific treatment nor a vaccine licensed for use in humans is available. This review is focused on general characteristic of Ebola viruses, its pathogenesis, immunological response of host, and recent approaches for vaccine development against EVD.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Year:  2015        PMID: 26558534     DOI: 10.1002/rmv.1863

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  8 in total

Review 1.  Neurological Complications of Ebola Virus Infection.

Authors:  Bridgette Jeanne Billioux; Bryan Smith; Avindra Nath
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

2.  The authors reply.

Authors:  Viranuj Sueblinvong; Daniel W Johnson; Gary L Weinstein; Michael J Connor; Ian Crozier; Allison M Liddell; Harold A Franch; Bruce R Wall; Andre C Kalil; Mark Feldman; Steven J Lisco; Jonathan E Sevransky
Journal:  Crit Care Med       Date:  2016-06       Impact factor: 7.598

Review 3.  The Role of Exosomal VP40 in Ebola Virus Disease.

Authors:  Michelle L Pleet; Catherine DeMarino; Benjamin Lepene; M Javad Aman; Fatah Kashanchi
Journal:  DNA Cell Biol       Date:  2017-02-08       Impact factor: 3.311

4.  Adipocytes are susceptible to Ebola Virus infection.

Authors:  Francoise A Gourronc; Michael R Rebagliati; Breanna Kramer-Riesberg; Anthony M Fleck; J J Patten; Kathleen Geohegan-Barek; Kelly N Messingham; Robert A Davey; Wendy Maury; Aloysius J Klingelhutz
Journal:  Virology       Date:  2022-05-27       Impact factor: 3.513

5.  Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction.

Authors:  Michelle L Pleet; Allison Mathiesen; Catherine DeMarino; Yao A Akpamagbo; Robert A Barclay; Angela Schwab; Sergey Iordanskiy; Gavin C Sampey; Benjamin Lepene; Sergei Nekhai; M J Aman; Fatah Kashanchi
Journal:  Front Microbiol       Date:  2016-11-07       Impact factor: 5.640

6.  Ebola virus mucin-like glycoprotein (Emuc) induces remarkable acute inflammation and tissue injury: evidence for Emuc pathogenicity in vivo.

Authors:  Yun-Jia Ning; Zhenyu Kang; Jingjun Xing; Yuan-Qin Min; Dan Liu; Kuan Feng; Manli Wang; Fei Deng; Yiwu Zhou; Zhihong Hu; Hualin Wang
Journal:  Protein Cell       Date:  2018-04       Impact factor: 14.870

Review 7.  Virus like particle-based vaccines against emerging infectious disease viruses.

Authors:  Jinliang Liu; Shiyu Dai; Manli Wang; Zhihong Hu; Hualin Wang; Fei Deng
Journal:  Virol Sin       Date:  2016-07-11       Impact factor: 4.327

Review 8.  Vaccinating for natural killer cell effector functions.

Authors:  Helen R Wagstaffe; Jason P Mooney; Eleanor M Riley; Martin R Goodier
Journal:  Clin Transl Immunology       Date:  2018-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.